Janux Therapeutics, Inc.
JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigenā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$34.69
Price-0.14%
-$0.05
1Y
Price
Market Cap
$2.086b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-238.1%
EBITDA Margin-243.1%
Net Profit Margin-129.5%
Free Cash Flow MarginRevenue
$10m
-5.5%
1y CAGR+6.4%
3y CAGR+39.0%
5y CAGREarnings
-$101.895m
-47.7%
1y CAGR-19.5%
3y CAGR-37.9%
5y CAGREPS
-$1.68
-31.2%
1y CAGR-5.0%
3y CAGR-26.9%
5y CAGRBook Value
$976.555m
$1.025b
Assets$48.211m
Liabilities$22.660m
DebtDebt to Assets
2.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$71.397m
-61.6%
1y CAGR-17.4%
3y CAGR-54.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company